interferon - for COVID-19 method

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA
clinical improvement 3.92 [1.66, 9.24]> 10%1 study (1 / -)99.9 %some concernnot evaluable moderatecrucial-
clinical improvement (time to event analysis only) 3.92 [1.66, 9.24]> 10%1 study (1 / -)99.9 %some concernnot evaluable moderatecrucial-
deaths 0.47 [0.01, 24.30]< 10%1 study (1 / -)64.2 %some concernnot evaluable moderatecrucial-
PCR-negative conversion 4.37 [1.86, 10.25]> 10%1 study (1 / -)100.0 %some concernnot evaluable moderateimportant-
PCR-negative conversion (time to event analysis only) 4.37 [1.86, 10.25]> 10%1 study (1 / -)100.0 %some concernnot evaluable moderateimportant-
serious adverse events 0.23 [0.01, 7.12]< 10%1 study (1 / -)79.4 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 87,95,94,90,91,97 90